Distilled to three letters

Start with the tissue, not the molecule. Sigumir is a peptide complex extracted from the cartilage and bone of young animals — a heterogeneous soup of fragments running from about 75 to 10,000 daltons, sold in Russia as a food supplement for aching joints. It is the kind of preparation modern pharmacology is trained to distrust: a crude extract doing something, with no single active ingredient named.

So the St. Petersburg Institute of Bioregulation and Gerontology did the reductionist thing and asked the extract what, exactly, was doing the work. Run through MALDI mass spectrometry and liquid chromatography–mass spec, the cartilage complex gave up a recurring short sequence: a tripeptide, Ala–Glu–Asp — three letters, A–E–D. Synthesized on its own, that fragment reportedly carried much of the parent complex’s activity. The isolated tripeptide is sold as Cartalax.

If that shape of story feels familiar, it should. It is the same move that gave the melanocortin family its cleanest fragment — take a large, busy source, find the smallest piece that still does the interesting thing, and keep only that. Where KPV was cut from a single 13-residue hormone, Cartalax was distilled out of a whole tissue. The premise underneath is far bolder, and that is where the scepticism has to start.

Osteoarthritis is, at the cellular level, a demographics problem inside the cartilage. Chondrocytes — the only cells hyaline cartilage has — stop dividing and start dying. Oxidative stress from the inflamed joint pushes up p53, the tumour-suppressor that also serves as the trigger for programmed cell death, so more chondrocytes commit apoptosis. At the same time their proliferative reserve falls, and cartilage that cannot replace its own cells cannot repair its matrix.

The claim for AED is that it reaches into that balance and moves both dials the right way at once. In cultured cartilage explants from rats, Cartalax and the parent Sigumir raised the area index — a measure of how far chondrocytes migrate and divide out from a cartilage fragment — by 18 to 38 percent. Alongside that, the peptides raised PCNA, the proliferation marker that rides with DNA polymerase during cell division, and lowered p53. Less of the apoptosis trigger, more of the division machinery: chondrocytes that had gone quiet were reported to start dividing again.

There is a second, separate line for bone. Cartalax was studied in rats whose bone density had been driven down — by ovariectomy in one model (an analogue of post-menopausal osteoporosis) and by removing the pineal gland in another. In the pineal model the tripeptide restored the number and function of the thyroid’s calcitonin-producing C-cells — calcitonin being the hormone that opposes bone resorption. That is the thread tying this molecule to the calcium & bone axis rather than to cartilage alone.

A tripeptide is far too small to fold into a lock-and-key ligand for a cell- surface receptor. So the Khavinson school proposes something else entirely, and it is the boldest mechanistic claim in peptide science: that these “short peptide bioregulators” pass through the cell and nuclear membranes, enter the nucleus, and bind DNA directly — each short sequence recognising a particular stretch of the double helix and nudging specific genes on or off. In this reading AED is assigned to an ACCT motif, and the p53/PCNA shift is downstream of that binding — the peptide acting as a tiny epigenetic dial rather than a hormone.

It is a genuinely elegant idea, and it is not physically absurd — sequence-specific minor-groove binding by small molecules is real, and peptides as epigenetic modulators is a live research area. What should make a careful reader slow down is that almost the entire edifice — the sequences, the binding motifs, the tissue-specificity, the clinical results — comes from a single institute and its collaborators, published largely in one literature, and has not been reproduced at scale by independent groups. A mechanism this sweeping, resting this heavily on one source, is exactly the kind of claim the rest of the field is right to want replicated before it believes it.

The mechanism is a pleasure to follow, which is exactly where the site’s creed — bullish on the science, sceptical on the page — has to earn its keep. Cartalax is sold and studied as an oral capsule, and the human data behind it is thinner than the confident marketing implies.

• The trials are open-label add-ons. In knee-osteoarthritis patients, Cartalax was given on top of conventional treatment and reduced pain in 55–63% of cases. There is no blinding, no placebo arm, and the endpoint is subjective pain — a design that cannot separate the peptide from the attention, the co-treatment, and expectancy.
• Nothing moved on the X-ray. The relief, such as it was, showed up in how patients felt, mainly at the earliest disease stages. Radiological measures of the joint did not change over the study. A cartilage-regeneration claim wants a structural readout; this evidence does not have one.
• It has to survive being eaten. A peptide swallowed is, chemically, food. A tripeptide is small enough to be a plausible substrate for the gut's PepT1 transporter rather than fully digested — the same loophole that lets KPV work orally — but whether an intact, meaningful dose of AED reaches cartilage or bone in a person is assumed here, not demonstrated.

So both halves of the honest sentence are true at once. Cartalax sits on a mechanistic idea that is one of the most interesting in the field — distil a tissue to a tripeptide, and have that tripeptide tune the genes of the cells that build the tissue — and on a human evidence base that is open-label, subjective, and effectively single-source. The elegance is real; the proof, for now, is not. Treat the arresting mechanism as a reason to watch the independent literature, not as a result that has already come in.